XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial

Abstract Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT03950154) assessed the efficacy and adverse events (AEs) o...

詳細記述

書誌詳細

主要な著者:	Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Publishing Group 2024-04-01
シリーズ:	Signal Transduction and Targeted Therapy
オンライン･アクセス:	https://doi.org/10.1038/s41392-024-01788-2
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!